Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

Andrea Casadei Gardini; Emanuela Scarpi; Luca Faloppi; Mario Scartozzi; Nicola Silvestris; Daniele Santini; Giorgio de Stefano; Giorgia Marisi; Francesca V. Negri; Francesco Giuseppe Foschi; Martina Valgiusti; Giorgio Ercolani; Giovanni Luca Frassineti

doi:10.18632/oncotarget.11565

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

Andrea Casadei Gardini _, Emanuela Scarpi, Luca Faloppi, Mario Scartozzi, Nicola Silvestris, Daniele Santini, Giorgio de Stefano, Giorgia Marisi, Francesca V. Negri, Francesco Giuseppe Foschi, Martina Valgiusti, Giorgio Ercolani and Giovanni Luca Frassineti

PDF | HTML | How to cite

Oncotarget. 2016; 7:67142-67149. https://doi.org/10.18632/oncotarget.11565

Metrics: PDF 2417 views | HTML 2975 views | ?

Abstract

Andrea Casadei Gardini1, Emanuela Scarpi2, Luca Faloppi3,4, Mario Scartozzi4, Nicola Silvestris5, Daniele Santini6, Giorgio de Stefano7, Giorgia Marisi8, Francesca V. Negri9, Francesco Giuseppe Foschi10, Martina Valgiusti1, Giorgio Ercolani11,12, Giovanni Luca Frassineti1

1Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy

2Unit of Biostatistics and Clinical Trials, IRST IRCCS, Meldola, Italy

3Department of Medical Oncology, Ospedale Generale Provinciale di Macerata ASUR Marche AV3, Macerata, Italy

4Department of Medical Oncology, University Hospital Cagliari, Cagliari, Italy

5Medical Oncology Unit, Cancer Institute “Giovanni Paolo II”, Bari, Italy

6Medical Oncology Department, University Campus Bio-Medico, Via Álvaro del Portillo, Rome, Italy

7Infectious Diseases and Interventional Ultrasound Unit, D. Cotugno Hospital, Naples, Italy

8Biosciences Laboratory, IRST IRCCS, Meldola, Italy

9Medical Oncology Unit, University Hospital, Parma, Italy

10DPT Internal Medicine, Faenza Hospital, Faenza, AUSL Romagna, Forli, Italy

11Department of General Surgery, Morgagni-Pierantoni Hospiatal, AUSL Romagna, Forli, Italy

12Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

Correspondence to:

Andrea Casadei Gardini, email: [email protected]

Keywords: systemic immune-inflammation index, inflammation, biomarker, hepatocellular carcinoma, neutrophil-to-lymphocyte ratio

Received: June 21, 2016 Accepted: August 15, 2016 Published: August 24, 2016

ABSTRACT

We evalueted a systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. 56 advanced HCC patients receiving sorafenib were available for our analysis. Lymphocyte, neutrophil and platelet were measured before beginning of treatment and after one month. Patient with SII ≥ 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) and OS (5.6 vs. 13.9 months, P = 0.027) with respect to patients with SII < 360.

NLR ≥ 3 had a lower median PFS (2.6 vs. 3.3 months, P < 0.049) but not OS (5.6 vs. 13.9 months, P = 0.062) than those with NLR < 3. After adjusting for clinical covariates SII and NLR remained an independent prognostic factor for OS. The SII and NLR represent potential prognostic indicator in patients with advanced HCC treated with sorafenib.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11565

Publication Alerts

Research Papers:

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

Abstract